&nbsp;

Dec 1969

Drug

isatuximab

Other Name(s): Sarclisa®

Quick Link(s):

Dec 1969

Regimen

BEVA+PEMB(MNT)

Cancer Type:

Gynecologic,

Cervix

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix

New Drug Funding Program

Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

Drugs Used:

pembrolizumab,

bevacizumab

Quick Link(s):

Regimen Monograph

Nov 2023

Drug

sacituzumab govitecan

Other Name(s): Trodelvy®

Quick Link(s):

Jul 2025

Drug

Enhertu trastuzumab deruxtecan

Other Name(s): Enhertu®

Quick Link(s):

Dec 1969

Regimen

TECL; TECL(RAMP)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Teclistamab (Outpatient) - Relapsed or Refractory Multiple Myeloma

High Cost Therapy Funding Program

Teclistamab (Inpatient) - Relapsed or Refractory Multiple Myeloma

Drugs Used:

teclistamab

Quick Link(s):

Regimen Monograph

Jul 2025

Regimen

BORTDEXALENA+DARA; LENA+DARA(MNT)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant

ODB - General Benefit

dexamethasone

Drugs Used:

daratumumab (Unfunded),

bortezomib (Unfunded),

lenalidomide (Unfunded),

dexamethasone

Quick Link(s):

Regimen Monograph

Drug

crisantaspase recombinant

Other Name(s): Rylaze™

Quick Link(s):

Dec 1969

Regimen

LENV+PEMB

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

lenvatinib - In Combination with Pembrolizumab for First-Line Advanced or Metastatic Renal Cell Carcinoma

New Drug Funding Program

Pembrolizumab - In Combination with Lenvatinib for First-Line Advanced or Metastatic Renal Cell Carcinoma

Drugs Used:

lenvatinib,

pembrolizumab

Quick Link(s):

Regimen Monograph

Regimen

PEMB

Cancer Type:

Lung,

Non-Small Cell

Intent: Adjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Adjuvant Treatment for Non-Small Cell Lung Cancer

Drugs Used:

pembrolizumab

Quick Link(s):

Regimen Monograph

Updated

Sep 2025

Regimen

TRIFTIPI+BEVA

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

Exceptional Access Program

trifluridine / tipiracil - In combination with bevacizumab for treatment of metastatic colorectal cancer, according to clinical criteria

New Drug Funding Program

Bevacizumab (Biosimilar) - In Combination with Trifluridine and Tipiracil for Previously Treated Metastatic Colorectal Cancer

trifluridine / tipiracil,

Drugs Used:

bevacizumab

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

BORTDEXALENA(LD)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Pre-SCT

ODB Limited Use

lenalidomide - Induction therapy for transplant eligible, newly diagnosed multiple myeloma, according to clinical criteria

ODB - General Benefit

dexamethasone

Drugs Used: